These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39192887)

  • 1. Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.
    Ko HC; Seager RJ; Pabla S; Senosain MF; Van Roey E; Gao S; Strickland KC; Previs RA; Green MF; Cooper M; Nesline MK; Hastings SB; Amoah KA; Zhang S; Conroy JM; Jensen TJ; Eisenberg M; Caveney B; Severson EA; Ramkissoon S; Gandhi S
    Breast Cancer (Dove Med Press); 2024; 16():483-495. PubMed ID: 39192887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between human epidermal growth factor receptor 2 status, namely low and zero expression, and prognosis in hormone receptor-positive breast cancer: a single-center retrospective study.
    Hara Y; Yano H; Ishida Y; Iwasaki K; Yamaguchi R
    Transl Cancer Res; 2024 Apr; 13(4):1773-1785. PubMed ID: 38737680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.
    Acs B; Hartman J; Sönmez D; Lindman H; Johansson ALV; Fredriksson I
    Lancet Reg Health Eur; 2024 May; 40():100886. PubMed ID: 38745990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics.
    Khalil MA; Habibian L; Martin C; Semaan K; Khaddage A; El Kassis N; Kesserouani C; Kourie HR; Atallah D
    Ann Diagn Pathol; 2024 Oct; 72():152326. PubMed ID: 38759564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
    Hu Y; Jones D; Zhao W; Tozbikian G; Wesolowski R; Parwani AV; Li Z
    Mod Pathol; 2023 Jul; 36(7):100164. PubMed ID: 36967073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
    Massa D; Vernieri C; Nicolè L; Criscitiello C; Boissière-Michot F; Guiu S; Bobrie A; Griguolo G; Miglietta F; Vingiani A; Lobefaro R; Taurelli Salimbeni B; Pinato C; Schiavi F; Brich S; Pescia C; Fusco N; Pruneri G; Fassan M; Curigliano G; Guarneri V; Jacot W; Dieci MV
    J Natl Cancer Inst; 2024 Jul; ():. PubMed ID: 39083015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction.
    Li M; Zhou S; Lv H; Cai M; Wan X; Lu H; Shui R; Yang W
    Arch Pathol Lab Med; 2024 Apr; 148(4):461-470. PubMed ID: 37406289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
    Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
    Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression.
    Rosso C; Voutsadakis IA
    Clin Breast Cancer; 2022 Jun; 22(4):391-397. PubMed ID: 35337735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
    Kunc M; Popęda M; Niemira M; Szałkowska A; Bieńkowski M; Pęksa R; Łacko A; Radecka BS; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Iżycka-Świeszewska E; Krętowski A; Żaczek AJ; Biernat W; Senkus-Konefka E
    Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32825530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
    Pabla S; Seager RJ; Van Roey E; Gao S; Hoefer C; Nesline MK; DePietro P; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Schoenborn M; Zhang S; Klein R; Glenn ST; Conroy JM
    Biomark Res; 2021 Jul; 9(1):56. PubMed ID: 34233760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.